semaglutide ema Ozempic® Gains Support for Kidney Risk Label Update EMA reviews Novo Nordisk drugs

Glucagonlike peptide1 receptor agonists (GLP1RAs) are widely used for type 2 diabetes (T2DM) and obesity, but their potential association with thyroid cancer remains a concern

In new guidelines, the American Society of Anesthesiologists (ASA) and other professional groups recommend that most patients using glucagon-like peptide-1 (GLP-1) receptor agonists can continue their medication regimen prior to elective surgery

Semaglutide was originally developed for type 2 diabetes, but clinical research shows it effectively reduces body weight in people without diabetes

Weightloss, Semaglutide diet, Weight loss pills for women

The purpose of this article is to provide a clear, evidence-based discussion on semaglutide and its relationship to heart palpitations.

Provider-led weight loss with GLP-1 medications